![Mark Hagler](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark Hagler
Corporate Officer/Principal chez
NOVABRIDGE BIOSCIENCES
Fortune : 194 964 $ au 30/06/2026
Profil
Mark A. Hagler is currently Chief Financial Officer & Director at SLAM BioTherapeutics, Inc. Mr. Hagler is also set to be Chief Commercial Officer at NovaBridge Biosciences starting in 2026.
Mr. Hagler holds an MBA from The Johns Hopkins University and an undergraduate degree from the United States Naval Academy.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 24/04/2026 | 230 000 ( 0,12% ) | 194 964 $ | 30/06/2026 |
Postes actifs de Mark Hagler
| Sociétés | Poste | Début |
|---|---|---|
| NOVABRIDGE BIOSCIENCES | Corporate Officer/Principal | 01/07/2026 |
Formation de Mark Hagler
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
16
Relations au 1er degré
3
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
The Johns Hopkins University
 The Johns Hopkins University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
United States Naval Academy
 United States Naval Academy Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
I-Mab
 I-Mab Pharmaceuticals: MajorHealth Technology Develops and manufactures medicines for cancer and autoimmune diseases | Health Technology |
